Background: Originally defined as an antiepileptic drug, lamotrigine (LMT) is a phenyltriazine derivative. Objective: It is the objective of this literature review to assess the clinical epidemiological profile, pathological mechanisms, and management of movement disorders associated with lamotrigine. Methods: Two reviewers without language restrictions found and evaluated pertinent records in six databases. Exclusions were made for reports indicating the usage of LMT only caused tremor or ataxia. Results: A total of 108 cases from 19 countries were evaluated in 48 reports. Nineteen tics, twenty-one dyskinesias, fourteen myoclonus, thirteen parkinsonism, ten dystonia, and one stuttering were among the movement disorders linked to LMT that were discovered. Ten cases of akathisia, four cases of myoclonus, four cases of cerebellar syndromes, one case of hypertonia, one case of dyskinesia, and an undetermined number of cases of dystonia were among the cases. The reported age ranged from 1.574 years to 33.34 years on average. Epilepsy was the most prevalent LMT indication, while men were the most common sex. At the commencement of the movement condition, the average LMT dosage was 228 mg. In 81% of cases, the onset of movement disturbance occurred within 6 months of the start of LMT. In 83% of cases, the recovery period from LMT cessation was less than one month. LMT withdrawal was the most widely used management strategy. Conclusions: Movement disorder start, and recovery times are rarely described, and most instances in the literature did not provide a clear image of the individual. We think that a dose adjustment depending on the advantages and side effects, carefully considered case by case, can be made prior to cessation of LMT.
Y. et al. (Tue,) studied this question.